Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes

NCT ID: NCT02159638

Last Updated: 2017-12-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-05-31
• Study Completion Date: 2014-09-01

Brief Summary

Continuous glucose monitoring (CGM) is a tool used in the treatment of patients with type 1 diabetes. A continuous glucose monitor (CGM) is a subcutaneous tissue sensor, which provides a tissue fluid glucose measurement every 1 to 5 minutes. Since CGM measure the glucose level by a sensor in subcutaneous tissue, there is uncertainty in the estimation of blood glucose levels. The accuracy of a certain CGM system can be assessed by comparing the glucose levels estimated by CGM with measured glucose levels in plasma. In the current study, we will compare the accuracy of the 2 CGM systems available on the market for clinical use in patients with type 1 diabetes. The aim of the current study is to evaluate effectiveness, safety and treatment satisfaction with 2 different CGM systems among adult type 1 diabetic patients.

Detailed Description

Each study patient will have both subcutaneous tissue CGM sensors inserted. Each sensor will produce a maximum of 1,440 tissue fluid glucose measurements per 24 hours and 8,460 measurements during the 6 days in study. The plan is to study 36 to 50 ambulatory patients during the hole study period. The two CGM data sets (DexCom4G and Medtronic Enlite) will be compared to each other and the time-matched reference blood glucose measurements.

The HemoCue Analyser- venous blood and finger-stick blood in cuvette, will be used to measure the concentration of glucose.

Each ambulatory patient will sample capillary blood and measure the concentration of glucose 6 to 10 times per day for max 6 days. The concentration of finger-stick capillary blood glucose will be measured using the HemoCue meter in their daily living and additionally a HemoCue Analyser at research visits using a lancet. Each patient will be admitted to the clinical research unit (CRU) for 7 measurements of venous samples at two occasions: on day 1-3 and 4-6 of the study with an interval of at least 15 minutes. An intravenous catheter will be inserted to facilitate blood sample acquisition each of these days of study. Three capillary finger-stick blood will be sampled at these 2 occasions, 1 at the first venous measurement (one day of days 1-3) and one at the last venous sample (one day of days 4-6).

Blood sample acquisition and handling will be standardized to minimize pre-analytical error.

The sensor insertion sites will be observed to detect bleeding, inflammation and infection of the skin or subcutaneous tissue. Insertion sites will be photographed if any abnormal findings exist at the end of the study for the individual patient.

The subjects will record self monitoring of blood glucose (SMBG), meal, and activity data in a written diary.

Conditions

Diabetes Mellitus, Type 1; Blood Glucose

Keywords

Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Insulin-Dependent; Endocrine System Diseases; Blood glucose; Blood Glucose, Self-Monitoring

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

comparisson CGM accuracy

Each patient will have both subcutaneous tissue CGM sensors (Guardian Enlite sensor and Dexcom G4 Platinum sensor) inserted at the same time. The HemoCue Analyser- venous blood and finger-stick blood in cuvette, will be used to measure the concentration of glucose

Group Type: OTHER

Guardian Enlite sensor

Intervention Type: DEVICE

Sensor insertion

Dexcom G4 platinum sensor

Intervention Type: DEVICE

Sensor insertion

Interventions

Guardian Enlite sensor

Sensor insertion

Intervention Type: DEVICE

Dexcom G4 platinum sensor

Sensor insertion

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Type 1 diabetes

2. Adult patients, age 18 or older and <75 years.

3. Written Informed Consent

Exclusion Criteria

1. Pregnancy

2. Patients with severe cognitive dysfunction or other disease which makes CGM use difficult.

3. Patients requiring continuous use of paracetamol. Paracetamol must not have been used

the week before the study and shall not be used during the duration because it disturbs the

interpretation of blood glucose levels estimated by the DexCom4G. However, other pain

killers can be used throughout the study period.

4. Current CGM use

5. History of allergic reaction to any of the CGMS materials

or adhesives in contact with the skin.

6. History of allergic reaction to chlorhexidine or alcohol

anti-septic solution.

7. Abnormal skin at the anticipated glucose sensor

attachment sites (excessive hair, burn, inflammation,

infection, rash, and/or tattoo).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Vastra Gotaland Region

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

NU-hospital Organisation

Trollhättan, , Sweden

Uddevalla hospital

Uddevalla, , Sweden

Countries

Sweden

References

Matuleviciene V, Joseph JI, Andelin M, Hirsch IB, Attvall S, Pivodic A, Dahlqvist S, Klonoff D, Haraldsson B, Lind M. A clinical trial of the accuracy and treatment experience of the Dexcom G4 sensor (Dexcom G4 system) and Enlite sensor (guardian REAL-time system) tested simultaneously in ambulatory patients with type 1 diabetes. Diabetes Technol Ther. 2014 Nov;16(11):759-67. doi: 10.1089/dia.2014.0238. Epub 2014 Sep 18.

Reference Type: DERIVED

PMID: 25233297 (View on PubMed)

Other Identifiers

VGFOUREG-387191

Identifier Type: -

Identifier Source: org_study_id